Varaico: Literature-Extracted Genetic Variants

Gene:EGFR
Variant:p.L747fs
Back to variants list

EGFR

NM_005228.5:p.L747fs

Associated Papers

Multi-gene panel sequencing reveals the relationship between driver gene mutation and clinical characteristics in lung adenocarcinoma.

Li J et al.

Discover Oncology, 2025

40053265 (PubMed )
Supplement: 12672_2025_2008_MOESM1_ESM.xlsx › Table_S2

Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing.

Shiraishi N et al.

Thoracic Cancer, 2025

Genomic landscape and tumor mutational features of resected preinvasive to invasive lung adenocarcinoma.

Lin Y et al.

Frontiers in Oncology, 2024

38803537 (PubMed )
Supplement: Table_1.xlsx › Table_S4

Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.

Du Z et al.

Biomolecules, 2023

36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S1

Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor.

Ku BM et al.

Oncology, 2022

The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics.

Tang M et al.

Nature Communications, 2021

34873156 (PubMed )
Supplement: 41467_2021_27341_MOESM1_ESM.pdf

Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer.

Vichas A et al.

Nature Communications, 2021

34373451 (PubMed )
Supplement: 41467_2021_24841_MOESM10_ESM.xlsx › sheet1

Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary Component.

Zhang S et al.

Frontiers in Oncology, 2021

34221970 (PubMed )
Supplement: Table_5.xlsx › Supplementary_Table_S5

Longitudinal multi-gene panel assessment of circulating tumor DNA revealed tumor burden and molecular characteristics along treatment course of non-small cell lung cancer.

Ho GYF et al.

Translational Lung Cancer Research, 2020

Tumor Mutation Signature Reveals the Risk Factors of Lung Adenocarcinoma with EGFR or KRAS Mutation.

Wang J et al.

Cancer Control : Journal of the Moffitt Cancer Center, 0

39760242 (PubMed )
Supplement: sj-xlsx-2-ccx-10.1177_10732748241307363.xlsx › MSK
Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."